The future of oral weight loss medication looks bright. Drug manufacturer Novo Nordisk announced a new experimental ...

Medical researchers have found that people who take the semaglutide-based drugs Ozempic and Wegovy may be less likely to die ...

Here is our list of the 15 unhealthiest countries in Europe. Insider Monkey Score: 14.5 ...

Researchers attempt to identify 15 Medicare Part D drugs with the highest risk of facing the U.S. government's ...

Hundreds of Americans have filed lawsuits in multiple states against pharmaceutical giants Novo Nordisk and Eli Lilly, ...

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top ...

Plus the week included a stop in Detroit by Lael Brainard, the director of the National Economic Council, who spoke to the ...

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...

European stocks face a series of hurdles to extend their 2024 rally after hitting another record high this week.

The controversy surrounding Ozempic, a popular diabetes medication turned weight-loss solution, has exploded as victims of severe side effects unite to file lawsuits against its manufacturers, Novo ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

The Senate investigation showed Americans pay $1,349 a month for the weight-loss drug Wegovy, which is priced at $92 in the United Kingdom.